Global Preclinical Molecular Imaging Market

Preclinical Molecular Imaging Comprehensive Study by Type (Equipment/Device, Reagents and Imaging Agents, Service), Equipment Type (MRI, MPI, Ultrasound, Preclinical Nuclear Imaging Systems (SPECT, PET, Trimodality (Spect/PET/CT) Systems, Others (Optical Molecular Imaging Device, Photoacoustic Imaging Systems)), Research Disease (Oncology, Cardiology, Neurology, Diabetes, Others), Reagent (MRI Contrast Agents, MPI (nanoparticles), Ultrasound, Nuclear Imaging Contrast Agents, Others) Players and Region - Global Market Outlook to 2024

Preclinical Molecular Imaging Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The global Preclinical Molecular Imaging market is expected to witness high growth in the forecasted period due to technological enhancement, new medical innovations. the significant development in the field of multimodality and optical imaging also helps to boost the global market. The growing demand for preventive care and early diagnosis is proliferating. Hence, several manufacturers in the market are identifying novel methods of disease detection, among which, molecular imaging is currently the most important development. As a functional imaging method molecular imaging aids in the characterization of the physiological events at the cellular and molecular levels.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledSiemens AG (Germany), Bruker BioSpin (United States), Toshiba (Japan), Aspect Imaging (Israel), Trifoil Imaging (United States), MILabs (Netherlands), Mediso Medical Imaging Systems (Hungary), Sedecal (Spain), Magnetic Insights, Inc. (United States) and Cubresa (Canada)


This growth is primarily driven by Increasing Demand for Multimodality Imaging and Growing Number of Cardiological Diseases.

Globally, a noticeable market trend is evident Growing Number of Government Initiatives The Health Care Technology sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Siemens AG (Germany), Bruker BioSpin (United States), Toshiba (Japan), Aspect Imaging (Israel), Trifoil Imaging (United States), MILabs (Netherlands), Mediso Medical Imaging Systems (Hungary), Sedecal (Spain), Magnetic Insights, Inc. (United States) and Cubresa (Canada), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 28th February 2019, Siemens Healthineers has announced that the new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been installed at the Hospital of the University of Pennsylvania (HUP) in Philadelphia – the first health care institution in the United States to install the technology.
On 1st March 2018, Siemens Healthineers launches Acuson Juniper next-generation ultrasound system. a new ultrasound system with advanced applications and imaging performance while featuring a lightweight, ergonomic design and complete maneuverability for use across a wide variety of clinical segments.

Influencing Trend:
Growing Number of Government Initiatives and The Growing Demand due to Early Detection of Diseases Using Molecular Imaging

Market Growth Drivers:
Increasing Demand for Multimodality Imaging and Growing Number of Cardiological Diseases

Challenges:
Stringent Government Regulation

Restraints:
High Cost Associated with Preclinical Molecular Imaging

Opportunities:
High Adoption due to Technological Advancements such as the Emergence of Next Generation of SPECT Cameras Contain Cadmium Zinc Telluride (CZT) Detectors and Introduction of AI-Enabled Imaging Technology

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Preclinical Molecular Imaging Market
- Analysis about New Entrants in Preclinical Molecular Imaging Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Preclinical Molecular Imaging Study Sheds Light on
— The Preclinical Molecular Imaging Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Preclinical Molecular Imaging industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Preclinical Molecular Imaging industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Equipment/Device
  • Reagents and Imaging Agents
  • Service
By Equipment Type
  • MRI
  • MPI
  • Ultrasound
  • Preclinical Nuclear Imaging Systems [SPECT, PET, Trimodality (Spect/PET/CT) Systems
  • Others (Optical Molecular Imaging Device, Photoacoustic Imaging Systems)

By Research Disease
  • Oncology
  • Cardiology
  • Neurology
  • Diabetes
  • Others

By Reagent
  • MRI Contrast Agents
  • MPI (nanoparticles)
  • Ultrasound
  • Nuclear Imaging Contrast Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Multimodality Imaging
      • 3.2.2. Growing Number of Cardiological Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulation
    • 3.4. Market Trends
      • 3.4.1. Growing Number of Government Initiatives
      • 3.4.2. The Growing Demand due to Early Detection of Diseases Using Molecular Imaging
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Preclinical Molecular Imaging, by Type, Equipment Type , Research Disease , Reagent and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Preclinical Molecular Imaging (Value)
      • 5.2.1. Global Preclinical Molecular Imaging by: Type (Value)
        • 5.2.1.1. Equipment/Device
        • 5.2.1.2. Reagents and Imaging Agents
        • 5.2.1.3. Service
      • 5.2.2. Global Preclinical Molecular Imaging by: Reagent (Value)
        • 5.2.2.1. MRI Contrast Agents
        • 5.2.2.2. MPI (nanoparticles)
        • 5.2.2.3. Ultrasound
        • 5.2.2.4. Nuclear Imaging Contrast Agents
        • 5.2.2.5. Others
      • 5.2.3. Global Preclinical Molecular Imaging Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Preclinical Molecular Imaging (Price)
      • 5.3.1. Global Preclinical Molecular Imaging by: Type (Price)
  • 6. Preclinical Molecular Imaging: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Siemens AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bruker BioSpin (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Toshiba (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aspect Imaging (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Trifoil Imaging (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MILabs (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mediso Medical Imaging Systems (Hungary)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sedecal (Spain)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Magnetic Insights, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cubresa (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Preclinical Molecular Imaging Sale, by Type, Equipment Type , Research Disease , Reagent and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Preclinical Molecular Imaging (Value)
      • 7.2.1. Global Preclinical Molecular Imaging by: Type (Value)
        • 7.2.1.1. Equipment/Device
        • 7.2.1.2. Reagents and Imaging Agents
        • 7.2.1.3. Service
      • 7.2.2. Global Preclinical Molecular Imaging by: Reagent (Value)
        • 7.2.2.1. MRI Contrast Agents
        • 7.2.2.2. MPI (nanoparticles)
        • 7.2.2.3. Ultrasound
        • 7.2.2.4. Nuclear Imaging Contrast Agents
        • 7.2.2.5. Others
      • 7.2.3. Global Preclinical Molecular Imaging Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Preclinical Molecular Imaging (Price)
      • 7.3.1. Global Preclinical Molecular Imaging by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Preclinical Molecular Imaging: by Type(USD Million)
  • Table 2. Preclinical Molecular Imaging Equipment/Device , by Region USD Million (2016-2021)
  • Table 3. Preclinical Molecular Imaging Reagents and Imaging Agents , by Region USD Million (2016-2021)
  • Table 4. Preclinical Molecular Imaging Service , by Region USD Million (2016-2021)
  • Table 5. Preclinical Molecular Imaging: by Reagent(USD Million)
  • Table 6. Preclinical Molecular Imaging MRI Contrast Agents , by Region USD Million (2016-2021)
  • Table 7. Preclinical Molecular Imaging MPI (nanoparticles) , by Region USD Million (2016-2021)
  • Table 8. Preclinical Molecular Imaging Ultrasound , by Region USD Million (2016-2021)
  • Table 9. Preclinical Molecular Imaging Nuclear Imaging Contrast Agents , by Region USD Million (2016-2021)
  • Table 10. Preclinical Molecular Imaging Others , by Region USD Million (2016-2021)
  • Table 11. South America Preclinical Molecular Imaging, by Country USD Million (2016-2021)
  • Table 12. South America Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 13. South America Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 14. South America Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 15. South America Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 16. Brazil Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 17. Brazil Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 18. Brazil Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 19. Brazil Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 20. Argentina Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 21. Argentina Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 22. Argentina Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 23. Argentina Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 24. Rest of South America Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 26. Rest of South America Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 27. Rest of South America Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 28. Asia Pacific Preclinical Molecular Imaging, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 31. Asia Pacific Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 32. Asia Pacific Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 33. China Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 34. China Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 35. China Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 36. China Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 37. Japan Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 38. Japan Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 39. Japan Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 40. Japan Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 41. India Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 42. India Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 43. India Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 44. India Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 45. South Korea Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 46. South Korea Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 47. South Korea Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 48. South Korea Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 49. Taiwan Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 50. Taiwan Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 51. Taiwan Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 52. Taiwan Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 53. Australia Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 54. Australia Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 55. Australia Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 56. Australia Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 57. Rest of Asia-Pacific Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 58. Rest of Asia-Pacific Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 61. Europe Preclinical Molecular Imaging, by Country USD Million (2016-2021)
  • Table 62. Europe Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 63. Europe Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 64. Europe Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 65. Europe Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 66. Germany Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 67. Germany Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 68. Germany Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 69. Germany Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 70. France Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 71. France Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 72. France Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 73. France Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 74. Italy Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 75. Italy Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 76. Italy Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 77. Italy Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 78. United Kingdom Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 79. United Kingdom Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 80. United Kingdom Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 81. United Kingdom Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 82. Netherlands Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 83. Netherlands Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 84. Netherlands Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 85. Netherlands Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 86. Rest of Europe Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 87. Rest of Europe Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 88. Rest of Europe Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 89. Rest of Europe Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 90. MEA Preclinical Molecular Imaging, by Country USD Million (2016-2021)
  • Table 91. MEA Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 92. MEA Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 93. MEA Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 94. MEA Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 95. Middle East Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 96. Middle East Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 97. Middle East Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 98. Middle East Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 99. Africa Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 100. Africa Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 101. Africa Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 102. Africa Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 103. North America Preclinical Molecular Imaging, by Country USD Million (2016-2021)
  • Table 104. North America Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 105. North America Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 106. North America Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 107. North America Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 108. United States Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 109. United States Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 110. United States Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 111. United States Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 112. Canada Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 113. Canada Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 114. Canada Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 115. Canada Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 116. Mexico Preclinical Molecular Imaging, by Type USD Million (2016-2021)
  • Table 117. Mexico Preclinical Molecular Imaging, by Equipment Type USD Million (2016-2021)
  • Table 118. Mexico Preclinical Molecular Imaging, by Research Disease USD Million (2016-2021)
  • Table 119. Mexico Preclinical Molecular Imaging, by Reagent USD Million (2016-2021)
  • Table 120. Preclinical Molecular Imaging: by Type(USD/Units)
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Preclinical Molecular Imaging: by Type(USD Million)
  • Table 132. Preclinical Molecular Imaging Equipment/Device , by Region USD Million (2022-2027)
  • Table 133. Preclinical Molecular Imaging Reagents and Imaging Agents , by Region USD Million (2022-2027)
  • Table 134. Preclinical Molecular Imaging Service , by Region USD Million (2022-2027)
  • Table 135. Preclinical Molecular Imaging: by Reagent(USD Million)
  • Table 136. Preclinical Molecular Imaging MRI Contrast Agents , by Region USD Million (2022-2027)
  • Table 137. Preclinical Molecular Imaging MPI (nanoparticles) , by Region USD Million (2022-2027)
  • Table 138. Preclinical Molecular Imaging Ultrasound , by Region USD Million (2022-2027)
  • Table 139. Preclinical Molecular Imaging Nuclear Imaging Contrast Agents , by Region USD Million (2022-2027)
  • Table 140. Preclinical Molecular Imaging Others , by Region USD Million (2022-2027)
  • Table 141. South America Preclinical Molecular Imaging, by Country USD Million (2022-2027)
  • Table 142. South America Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 143. South America Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 144. South America Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 145. South America Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 146. Brazil Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 147. Brazil Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 148. Brazil Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 149. Brazil Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 150. Argentina Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 151. Argentina Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 152. Argentina Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 153. Argentina Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 154. Rest of South America Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 155. Rest of South America Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 156. Rest of South America Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 157. Rest of South America Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 158. Asia Pacific Preclinical Molecular Imaging, by Country USD Million (2022-2027)
  • Table 159. Asia Pacific Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 160. Asia Pacific Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 161. Asia Pacific Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 162. Asia Pacific Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 163. China Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 164. China Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 165. China Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 166. China Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 167. Japan Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 168. Japan Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 169. Japan Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 170. Japan Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 171. India Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 172. India Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 173. India Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 174. India Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 175. South Korea Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 176. South Korea Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 177. South Korea Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 178. South Korea Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 179. Taiwan Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 180. Taiwan Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 181. Taiwan Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 182. Taiwan Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 183. Australia Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 184. Australia Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 185. Australia Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 186. Australia Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 187. Rest of Asia-Pacific Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 188. Rest of Asia-Pacific Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 189. Rest of Asia-Pacific Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 191. Europe Preclinical Molecular Imaging, by Country USD Million (2022-2027)
  • Table 192. Europe Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 193. Europe Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 194. Europe Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 195. Europe Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 196. Germany Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 197. Germany Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 198. Germany Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 199. Germany Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 200. France Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 201. France Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 202. France Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 203. France Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 204. Italy Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 205. Italy Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 206. Italy Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 207. Italy Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 208. United Kingdom Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 209. United Kingdom Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 210. United Kingdom Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 211. United Kingdom Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 212. Netherlands Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 213. Netherlands Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 214. Netherlands Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 215. Netherlands Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 216. Rest of Europe Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 217. Rest of Europe Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 218. Rest of Europe Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 219. Rest of Europe Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 220. MEA Preclinical Molecular Imaging, by Country USD Million (2022-2027)
  • Table 221. MEA Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 222. MEA Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 223. MEA Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 224. MEA Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 225. Middle East Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 226. Middle East Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 227. Middle East Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 228. Middle East Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 229. Africa Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 230. Africa Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 231. Africa Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 232. Africa Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 233. North America Preclinical Molecular Imaging, by Country USD Million (2022-2027)
  • Table 234. North America Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 235. North America Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 236. North America Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 237. North America Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 238. United States Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 239. United States Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 240. United States Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 241. United States Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 242. Canada Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 243. Canada Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 244. Canada Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 245. Canada Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 246. Mexico Preclinical Molecular Imaging, by Type USD Million (2022-2027)
  • Table 247. Mexico Preclinical Molecular Imaging, by Equipment Type USD Million (2022-2027)
  • Table 248. Mexico Preclinical Molecular Imaging, by Research Disease USD Million (2022-2027)
  • Table 249. Mexico Preclinical Molecular Imaging, by Reagent USD Million (2022-2027)
  • Table 250. Preclinical Molecular Imaging: by Type(USD/Units)
  • Table 251. Research Programs/Design for This Report
  • Table 252. Key Data Information from Secondary Sources
  • Table 253. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Preclinical Molecular Imaging: by Type USD Million (2016-2021)
  • Figure 5. Global Preclinical Molecular Imaging: by Reagent USD Million (2016-2021)
  • Figure 6. South America Preclinical Molecular Imaging Share (%), by Country
  • Figure 7. Asia Pacific Preclinical Molecular Imaging Share (%), by Country
  • Figure 8. Europe Preclinical Molecular Imaging Share (%), by Country
  • Figure 9. MEA Preclinical Molecular Imaging Share (%), by Country
  • Figure 10. North America Preclinical Molecular Imaging Share (%), by Country
  • Figure 11. Global Preclinical Molecular Imaging: by Type USD/Units (2016-2021)
  • Figure 12. Global Preclinical Molecular Imaging share by Players 2021 (%)
  • Figure 13. Global Preclinical Molecular Imaging share by Players (Top 3) 2021(%)
  • Figure 14. Global Preclinical Molecular Imaging share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Siemens AG (Germany) Revenue: by Geography 2021
  • Figure 18. Bruker BioSpin (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bruker BioSpin (United States) Revenue: by Geography 2021
  • Figure 20. Toshiba (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Toshiba (Japan) Revenue: by Geography 2021
  • Figure 22. Aspect Imaging (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Aspect Imaging (Israel) Revenue: by Geography 2021
  • Figure 24. Trifoil Imaging (United States) Revenue, Net Income and Gross profit
  • Figure 25. Trifoil Imaging (United States) Revenue: by Geography 2021
  • Figure 26. MILabs (Netherlands) Revenue, Net Income and Gross profit
  • Figure 27. MILabs (Netherlands) Revenue: by Geography 2021
  • Figure 28. Mediso Medical Imaging Systems (Hungary) Revenue, Net Income and Gross profit
  • Figure 29. Mediso Medical Imaging Systems (Hungary) Revenue: by Geography 2021
  • Figure 30. Sedecal (Spain) Revenue, Net Income and Gross profit
  • Figure 31. Sedecal (Spain) Revenue: by Geography 2021
  • Figure 32. Magnetic Insights, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Magnetic Insights, Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Cubresa (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Cubresa (Canada) Revenue: by Geography 2021
  • Figure 36. Global Preclinical Molecular Imaging: by Type USD Million (2022-2027)
  • Figure 37. Global Preclinical Molecular Imaging: by Reagent USD Million (2022-2027)
  • Figure 38. South America Preclinical Molecular Imaging Share (%), by Country
  • Figure 39. Asia Pacific Preclinical Molecular Imaging Share (%), by Country
  • Figure 40. Europe Preclinical Molecular Imaging Share (%), by Country
  • Figure 41. MEA Preclinical Molecular Imaging Share (%), by Country
  • Figure 42. North America Preclinical Molecular Imaging Share (%), by Country
  • Figure 43. Global Preclinical Molecular Imaging: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Siemens AG (Germany)
  • Bruker BioSpin (United States)
  • Toshiba (Japan)
  • Aspect Imaging (Israel)
  • Trifoil Imaging (United States)
  • MILabs (Netherlands)
  • Mediso Medical Imaging Systems (Hungary)
  • Sedecal (Spain)
  • Magnetic Insights, Inc. (United States)
  • Cubresa (Canada)
Select User Access Type

Key Highlights of Report


Oct 2019 227 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Preclinical Molecular Imaging Market Quantitative research analysis
Global Preclinical Molecular Imaging Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Preclinical Molecular Imaging market are Siemens AG (Germany), Bruker BioSpin (United States), Toshiba (Japan), Aspect Imaging (Israel), Trifoil Imaging (United States), MILabs (Netherlands), Mediso Medical Imaging Systems (Hungary), Sedecal (Spain), Magnetic Insights, Inc. (United States) and Cubresa (Canada), to name a few.
North America is dominating the Preclinical Molecular Imaging Market.
"Stringent Government Regulation" is seen as one of the major challenges by many Industry Players of Preclinical Molecular Imaging Market
The Preclinical Molecular Imaging market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Preclinical Molecular Imaging market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Preclinical Molecular Imaging Market Report?

Have a Query? Click Here

Other Related Reports

Chemotherapy Comprehensive Study by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia, Ovarian Cancer, Others), Route of Administration (...
$ 3750
Prostate Cancer Nuclear Medicine Diagnostics Comprehensive Study by Type (Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET)), Application (Hospitals, Clinics, Oth...
$ 3800
Smart Medicine Bottles Comprehensive Study by Type (Smart Pill Boxes, Smart Pill Bottles, Others), Indication (Dementia, Cancer Management, Diabetes Care, Others), End Use (Home Care Settings, Specia...
$ 3450
Home Health Hub Comprehensive Study by Type (Standalone Hubs, Smartphone-based hubs, Services (Remote Patient Monitoring Services, Support & Maintenance Services)), Patient Monitoring (High-acuity Pa...
$ 3750
Urinary Self Catheter Comprehensive Study by Type (Intermittent Catheter, Uncoated Intermittent Catheters, Coated Intermittent Catheters, Antimicrobial intermittent catheters, Hydrophilic intermitten...
$ 3450
PACS Systems Comprehensive Study by Type (Radiology PACS, Cardiology PACS, Pathology PACS, Ophthalmology PACS, Orthopedics PACS, Oncology PACS, Dermatology PACS, Neurology PACS, Endoscopy PACS, Women...
$ 3650